Boji Pharmaceutical: Progress Announcement on the Use of Temporarily Idle Raised Funds for Cash Management and Expiry and Redemption
Boji Pharmaceuticals: Announcement on the completion of the cancellation of some restricted stock repurchases
Boji Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining an Invention Patent Certificate
Boji Pharmaceutical: Announcement on the company being recognized as a national specialized, special and new “little giant” enterprise
Boji Pharmaceutical: Announcement on the expiration and completion of the controlling shareholders\' unanimous action plan to reduce their holdings
Broge Pharmaceuticals: Announcement on the completion of cancellation of some stock options
Boji Pharmaceutical: Announcement on the cancellation of the pledge of part of the controlling shareholder\'s shares
Boji Pharmaceuticals: 300404 Boji Pharmaceuticals Investor Relations Management Information 20241028
Boji Pharmaceutical: Beijing Kangda (Guangzhou) Law Firm\'s Legal Opinion on the Company\'s Cancellation of Some Restricted Shares
Boji Pharmaceutical: Beijing Kangda (Guangzhou) Law Firm\'s Legal Opinion on the Company\'s Cancellation of Some Stock Options
Broge Pharmaceuticals: Announcement on the abolition of some restricted stocks
Boji Pharmaceuticals: Announcement on Accruing Asset Impairment Losses, Credit Impairment Losses, and Asset Write-off
Broge Pharmaceuticals: Announcement on Cancellation of Some Stock Options
Boji Pharmaceutical: Announcement of Resolutions of the 11th Meeting of the Fifth Board of Supervisors
Boji Pharmaceutical: Announcement of Resolutions of the 11th Meeting of the Fifth Board of Directors
Broge Pharmaceuticals: Report for the third quarter of 2024
Boji Pharmaceutical: Announcement on the Company Obtaining an Invention Patent Certificate
Broge Pharmaceuticals: Announcement on the progress of external guarantees
Boji Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining an Invention Patent Certificate
Boji Pharmaceutical: Progress Announcement on the Use of Temporarily Idle Raised Funds for Cash Management, Expiration, and Continued Cash Management
No Data
No Data